Estamos realizando la búsqueda. Por favor, espere...


Melatonin enhances the apoptotic effects and modulates the changes in gene expression induced by docetaxel in MCF 7 human breast cancer cells

Abstract: Results from clinical trials and multiple in vivo and in vitro studies point to melatonin as a promising adjuvant molecule with many beneficial effects when concomitantly administered with chemotherapy. Melatonin palliates side?effects and enhances the efficacy of chemotherapeutic agents. However, the mechanisms through which melatonin regulates molecular changes induced by chemotherapeutic agents remain largely unknown. In this study, we demonstrated that melatonin enhanced the anti-proliferative and apoptotic responses to low doses of docetaxel in breast cancer cells. Importantly, these effects were more potent when melatonin was added prior to docetaxel. Treatment with 1 µM docetaxel (equivalent to the therapeutic dosage) induced changes in gene expression profiles and melatonin modulated these changes. Specifically, docetaxel downregulated TP53, cyclin-dependent kinase inhibitor 1A (CDKN1A) and cadherin 13 (CDH13), and upregulated mucin 1 (MUC1), GATA binding protein 3 (GATA3) and c-MYC, whereas melatonin counteracted these effects. Melatonin further stimulated the expression of the pro-apoptotic BAD and BAX genes, and enhanced the inhibition of the anti-apoptotic gene BCL-2 induced by docetaxel. The findings of this study suggest that melatonin is a molecule with potential for use as an adjuvant in cancer chemotherapy, which may have implications for designing clinical trials using chemotherapeutic drugs in combination with melatonin.

 Fuente: Int J Oncol. 2018 Feb;52(2):560-570

Editorial: Spandidos Publications

 Fecha de publicación: 01/02/2018

Nº de páginas: 11

Tipo de publicación: Artículo de Revista

 DOI: 10.3892/ijo.2017.4213

ISSN: 1019-6439

Proyecto español: SAF2016-77103-P

Url de la publicación: https://dx.doi.org/10.3892/ijo.2017.4213